LAB•benzinga•
Standard BioTools Announced Preliminary Revenue For Q4 And FY 2024 Of Approximately $46.5M And $174M, Respectively, Compared To Consensus Of $43.03M And $171.20M
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 13, 2025 by benzinga